Cross-category comparison
ESG vs Wegovy Tablets
Different categories, normalised only where comparison is meaningful.
Endoscopic sleeve gastroplasty
Less average weight loss than sleeve/bypass but more substantial than lifestyle alone for selected patients; evidence base is growing
VS
Wegovy tablets
OASIS 4: mean -13.6% at 64 weeks under treatment-policy analysis; -16.6% estimated while on treatment without additional obesity therapy
Shared dimensions
| Dimension | Endoscopic sleeve gastroplasty | Wegovy tablets |
|---|---|---|
| Relative weight-loss potential / intensity | 6/10 | 8/10 |
| Typical speed / access to effect | 6/10 | 8/10 |
| Lower procedural / medical burden | 10/10 | 6/10 |
| Ease of stopping, reversing or changing route | 7/10 | 9/10 |
| Lower cost / easier access | 4/10 | 3/10 |
| Long-term maintenance simplicity | 9/10 | 6/10 |
| Evidence maturity / depth | 6/10 | 8/10 |
| Day-to-day or pathway convenience | 9/10 | 7/10 |
Category-specific detail
| Issue | Endoscopic sleeve gastroplasty | Wegovy tablets |
|---|---|---|
| Anatomical change | Internal endoscopic sutures reduce stomach volume without removing stomach tissue | Not applicable |
| Diabetes / metabolic | Metabolic benefit through weight loss; less evidence depth than bypass surgery | Not applicable |
| Evidence anchor | Not applicable | OASIS 4: mean -13.6% at 64 weeks under treatment-policy analysis; -16.6% estimated while on treatment without additional obesity therapy |
| How it works | Not applicable | GLP-1 receptor agonist |
| How taken | Not applicable | Daily tablet — Once daily |
| Main trade-offs | Not applicable | Daily dosing; Administration instructions and adherence matter; Newer UK formulation with less real-world maturity; NICE/NHS reimbursement position may differ from injectable Wegovy |
| Maintenance | Not applicable | Long-term treatment / maintenance planning still applies |
| NHS context | NHS now describes ESG as a weight-loss procedure, but availability is not universal | Licensed; NICE/NHS positioning may lag the new formulation and should be checked live |
| Nutrition burden | Lower malabsorptive burden because intestine is not bypassed | Not applicable |
| Procedure type | Endoscopic suturing procedure | Not applicable |
| Reflux | May be preferable to sleeve in some reflux contexts, but individual assessment matters | Not applicable |
| Reversible | Potentially revisable/reversible in some circumstances, but not equivalent to simply 'undoing' a band | Not applicable |
| Revision | Can be followed by surgical bariatric procedures in selected cases | Not applicable |
| UK licence | Not applicable | UK weight management licence |
Do not add the scores together.
The bars are there to expose trade-offs. They are not a validated overall suitability index.
Built for informed decisions. Our health content is evidence-led, regularly reviewed, and designed to explain options clearly without pretending a website can replace clinical assessment.
Continue exploring